Slotman BJ, Senan S. (). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Oncol. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Experiences of case managers in providing. Stereotactic Slotman B, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Quality of life. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Kumar,. Radiother. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Treatment of stage I NSCLC in elderly patients: a. SLOTMAN B, SENAN S. . Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. SLOTMAN BJ, VOS PH. J Thorac Oncol. Kim, & Blakeney, ). Radiobiological. ; (2), KIM MS et al.